Trade

with

Endocyte Inc
(NASDAQ: ECYT)
AdChoices
5.81
+0.20
+3.57%
After Hours :
5.81
0.00
0.00%

Open

5.62

Previous Close

5.61

Volume (Avg)

895.40k (1.41M)

Day's Range

5.57-5.87

52Wk Range

5.31-33.70

Market Cap.

233.10M

Dividend Rate ( Yield )

-

Beta

0.97

Shares Outstanding

41.55M

P/E Ratio (EPS)

16.26 (0.34)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 64.87M

    • Net Income

    • -18.03M

    • Market Cap.

    • 233.10M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 13.23

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.97

    • Forward P/E

    • -4.50

    • Price/Sales

    • 2.23

    • Price/Book Value

    • 1.12

    • Price/Cash flow

    • -4.18

      • EBITDA

      • -17.36M

      • Return on Capital %

      • 6.36

      • Return on Equity %

      • 8.70

      • Return on Assets %

      • 6.36

      • Book Value/Share

      • 5.17

      • Shares Outstanding

      • 41.55M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 21.00

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -1.26

        • Cashflow Estimate

        • -1.26

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 198.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 164.62

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 13.23

            • 39.38

            • Net Profit Margin

            • 13.23

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 8.42

              • 2.92

              • Quick Ratio

              • 8.27

              • 2.35

              • Interest Coverage

              • 7,253.40

              • 38.02

              • Leverage Ratio

              • 1.08

              • 2.21

              • Book Value/Share

              • 5.17

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 16.00

                • 243.90

                • P/E Ratio 5-Year High

                • 97.73

                • 634.30

                • P/E Ratio 5-Year Low

                • 8.76

                • 124.82

                • Price/Sales Ratio

                • 2.12

                • 9.29

                • Price/Book Value

                • 1.07

                • 8.39

                • Price/Cash Flow Ratio

                • -4.18

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 8.70

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 6.36

                    (-46.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 8.70

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 145.84k

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.48

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -18.34M
                  Operating Margin
                  -28.27
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.18
                  Ownership

                  Institutional Ownership

                  49.12%

                  Top 10 Institutions

                  34.76%

                  Mutual Fund Ownership

                  23.35%

                  Float

                  87.82%

                  5% / Insider Ownership

                  2.15%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    3,523,415

                  • -1.75

                  • 8.48

                  • Fidelity® Series Growth Company Fund

                  •  

                    868,900

                  • 0.00

                  • 2.09

                  • Bb Biotech AG

                  •  

                    683,522

                  • -72.25

                  • 1.66

                  • iShares Russell 2000 (AU)

                  •  

                    562,688

                  • -1.46

                  • 1.25

                  • iShares Nasdaq Biotechnology

                  •  

                    537,532

                  • -0.47

                  • 1.19

                  • Vanguard Total Stock Mkt Idx

                  •  

                    491,506

                  • 0.00

                  • 1.18

                  • Vanguard Extended Market Index Fund

                  •  

                    342,512

                  • 0.23

                  • 0.82

                  • iShares Russell 2000 Growth

                  •  

                    265,885

                  • 0.34

                  • 0.59

                  • Candriam Eqs L Biotechnology

                  •  

                    240,000

                  • 0.00

                  • 0.58

                  • Rydex Series Trust Biotechnology Fund

                  •  

                    200,249

                  • -5.88

                  • 0.48

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    5,404,572

                  • -11.20%

                  • 13.01

                  • BB Biotech AG

                  •  

                    2,463,522

                  • 0.00%

                  • 5.93

                  • BlackRock Fund Advisors

                  •  

                    1,399,074

                  • +7.74%

                  • 3.37

                  • Vanguard Group, Inc.

                  •  

                    1,032,244

                  • +1.88%

                  • 2.48

                  • Pinnacle Associates, Inc.

                  •  

                    987,223

                  • -4.68%

                  • 2.38

                  • Bellevue Asset Management AG

                  •  

                    683,522

                  • -72.25%

                  • 1.66

                  • State Street Corp

                  •  

                    605,674

                  • +19.36%

                  • 1.46

                  • Pacific Alternative Asset Mgmt Co, Llc

                  •  

                    522,800

                  • +799.67%

                  • 1.26

                  • TANG CAPITAL MANAGEMENT LLC

                  •  

                    465,763

                  • 0.00%

                  • 1.12

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Core

                  Endocyte, Inc. was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. It is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory dis...moreeases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The biotechnology and pharmaceutical industries are highly competitive. Currently, it owns 11 is...moresued U.S. patents in whole. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.lessless

                  Key People

                  Mr. P. Ron Ellis

                  CEO/Director/Founder/President

                  John C. Aplin,PhD

                  Chairman of the Board/Director

                  Dr. Philip S. Low, PhD

                  Chief Scientific Officer/Director/Founder

                  Mr. Michael A. Sherman

                  CFO/COO

                  Dr. Christopher P. Leamon, PhD

                  Vice President, Divisional

                  • Endocyte Inc

                  • 3000 Kent Avenue

                  • West Lafayette, IN 47906

                  • USA.Map

                  • Phone: +1 765 463-7175

                  • Fax: +1 765 463-9271

                  • endocyte.com

                  Incorporated

                  1995

                  Employees

                  91

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: